Wegovy users keep weight off for four years, Novo Nordisk study says
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker's case to insurers and governments to cover the cost of the effective but expensive drug.
Novo Nordisk’s Wegovy Sustains Weight Loss for Four Years in Two Studies
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy (semaglutide) provides cardiovascular benefits irrespective of starting weight and the amount of weight lost.
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
Novo Nordisk retains around 60% of the list price for its diabetes and obesity medications, Ozempic and Wegovy, after rebates and fees.
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
Novo Nordisk’s blockbuster diabetes drug Ozempic, known for its weight-loss side effects, can also help patients living ...
New peer-reviewed data published on Friday indicated that Novo Nordisk’s (NVO) GLP-1 agonist semaglutide, marketed as Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback